Cannabis Use Disorder Treatment Market to Reach USD 2.82 Billion by 2036 as Healthcare Systems Expand Evidence-Based Addiction Therapies

The cannabis use disorder treatment market is entering a structured growth phase as healthcare providers and rehabilitation networks increasingly prioritize evidence-based addiction management protocols, according to latest insights by future market insights. Rising disease prevalence, improved screening capabilities, and expanding reimbursement frameworks are accelerating adoption of advanced therapeutic interventions across hospitals, specialty clinics, and rehabilitation centers worldwide.

Get detailed market forecasts, competitive benchmarking, and pricing trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16495

Quick Stats Snapshot

• Market Size (2026): USD 1.78 billion
• Forecast Value (2036): USD 2.82 billion
• CAGR (2026-2036): 4.7%
• Incremental Opportunity: USD 1.04 billion
• Leading Type Segment: Marijuana (44.6% share)
• Leading Treatment Segment: Counselling & Behavioral Therapy (39.8% share)
• Fastest Growing Market: USA (5.1% CAGR)
• Strong Regional Market: EU (4.8% CAGR)

Market Size and Forecast: Structured Therapeutic Approaches Drive Market Expansion

The cannabis use disorder treatment market is projected to grow from USD 1.78 billion in 2026 to USD 2.82 billion by 2036, reflecting a CAGR of 4.7%. The market is evolving from a fragmented treatment category into a structured therapeutic ecosystem supported by clinical evidence, reimbursement modernization, and growing institutional adoption.

Healthcare systems are increasingly investing in disease management programs focused on early intervention, behavioral therapy integration, and patient compliance optimization across diverse healthcare settings.

Key Growth Drivers: Rising Disease Burden and Expanding Treatment Access

1. Increasing Disease Prevalence and Screening Rates
Growing awareness of cannabis dependency and improved diagnostic capabilities are supporting demand for specialized treatment solutions.

2. Regulatory Modernization and Clinical Guidelines
Updated treatment recommendations and regulatory approvals for emerging therapies are expanding the addressable patient population.

3. Expansion of Behavioral Therapy Programs
Healthcare institutions are increasingly prioritizing counselling and behavioral therapy programs as first-line treatment approaches.

4. Healthcare Infrastructure Investments in Emerging Markets
Rising healthcare expenditure across Asia and the Middle East is improving access to advanced treatment solutions.

Market Challenges: Cost Management and Reimbursement Constraints

Despite stable expansion, the industry continues to face operational and financial barriers:

• High treatment and clinical development costs
• Limited reimbursement coverage in price-sensitive markets
• Delayed regulatory approval timelines
• Patient compliance and relapse management challenges
• Restricted access to specialized treatment infrastructure

These factors continue to favor companies with strong clinical evidence, broad distribution capabilities, and established physician relationships.

Speak to Analyst: Customize insights for your business strategy:
https://www.futuremarketinsights.com/customization-available/rep-gb-16495

Segmentation Insights: Marijuana and Behavioral Therapy Lead Demand

By Type

• Marijuana leads with 44.6% market share in 2026
• Physician familiarity and established treatment protocols support segment dominance
• Synthetic treatment demand continues to expand gradually

By Treatment

• Counselling & Behavioral Therapy accounts for 39.8% share
• Institutional adoption and standardized procurement processes support growth
• Medication and detoxification services continue gaining traction

Regional Analysis: USA and EU Maintain Strong Growth Momentum

High-growth regions include:

• USA (5.1% CAGR): Advanced healthcare infrastructure and expanding treatment access support adoption
• EU (4.8% CAGR): Regulatory modernization and healthcare investment sustain market demand
• UK (4.5% CAGR): Clinical guideline adoption strengthens institutional procurement
• South Korea (4.2% CAGR): Healthcare system investments support treatment expansion
• Japan (3.5% CAGR): Healthcare modernization improves addressable patient population

Full Report for Detailed Insights:
https://www.futuremarketinsights.com/reports/cannabis-use-disorder-treatment-market

Competitive Landscape: Clinical Evidence and Distribution Access Define Leadership

The competitive landscape is shaped by regulatory approvals, therapeutic innovation, and healthcare distribution capabilities.

Key players include:

• Indivior PLC
• Zynerba Pharmaceuticals
• Pfizer Inc.
• GW Pharmaceuticals (Jazz Pharmaceuticals)
• Adial Pharmaceuticals
• Omeros Corporation
• BioCorRx Inc.

Companies are increasingly focusing on novel formulation technologies, behavioral therapy integration, and next-generation pharmacological approaches to strengthen competitive positioning.

Explore In-Depth Healthcare Market Insights:
https://www.futuremarketinsights.com/industry-analysis/healthcare

Future Outlook: Integrated Addiction Treatment Models Will Shape Market Evolution

Over the next decade, the cannabis use disorder treatment market is expected to benefit from expanding healthcare investment, evolving treatment protocols, and rising focus on preventive care strategies.

Clinical research into CB1 receptor modulators, digital therapy platforms, and evidence-based behavioral interventions is expected to reshape future treatment pathways while improving patient outcomes and long-term compliance.

Explore Industry Insights: https://www.futuremarketinsights.com/industry-analysis

Executive Takeaways

• The market is projected to reach USD 2.82 billion by 2036
• Marijuana remains the dominant type segment with 44.6% share
• Counselling & Behavioral Therapy leads treatment demand with 39.8% share
• USA remains the fastest-growing major market with 5.1% CAGR
• Regulatory modernization and reimbursement expansion continue supporting adoption
• Competitive differentiation increasingly depends on clinical evidence and treatment accessibility

Explore More Related Studies Published by FMI Research:

PARP Inhibitor Market https://www.futuremarketinsights.com/reports/parp-inhibitors-market

Biological Indicator Vial Market https://www.futuremarketinsights.com/reports/biological-indicator-vials-market

mRNA Cancer Vaccine Biologic Lines Market https://www.futuremarketinsights.com/reports/mrna-cancer-vaccine-biologic-lines-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com

About Future Market Insights (FMI)

Future Market Insights, Inc. is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization trusted by Fortune 500 companies. With a global presence across the U.S., UK, India, and Dubai, FMI delivers data-driven insights across 30+ industries and 1200 markets worldwide.

This release was published on openPR.